Latest news for Ping An Healthcare (OTC:PIAHY) Stock

Ping An Healthcare and Technology is the parent of Ping An Good Doctor, or PAGD, an online platform offering healthcare services in the form of a health maintenance organization, or HMO, model that provides commercial healthcare services and offers healthcare checkup, healthcare management, and corporate reimbursement for a fee. The company leverages the network of health providers from its parent Ping An Group, where it enters into contracts with physicians, hospitals, and specialists to offer their services to HMO participants. Other than commercial healthcare premium services, PAGD offers online consultations and prescription e-commerce online to individuals. The platform has 978 corporate clients and 43 million paying users. PAGD is 38.43% owned by its parent company.

PING AN HLTHCRE &TECH ADR by Ping An Healthcare & Technology Co Ltd.

Ping An Healthcare And Technology Co Ltd

The Dow Jones index closed lower by over 500 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Super League Enterprise</h3>
<ul>
<li>The Trade: Super League Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) Director Jeff Patrick Gehl <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 50,000 shares at</a> an average price of $1.35. To acquire these shares, it cost around $67,548.</li>
<li>What's Happening: On June 21, Super League issued a mid-year update from the Company's Chief Executive Office, Ann Hand.</li>
<li>What Super League Enterprise Does: Super League Enterprise Inc is the rocket ship to the metaverse.</li>
</ul>
<h3 class="wp-block-heading">aTyr Pharma</h3>
<ul>
<li>The Trade: aTyr Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) Director Paul Schimmel <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 100,000 shares </a>at an average price of $1.85. To acquire these shares, it cost around $184,613.</li>
<li>What's Happening: On July 22, HC Wainwright &amp; Co. analyst Joseph Pantginis reiterated aTyr Pharma with a Buy rating and maintained a $35 price target.</li>
<li>What aTyr Pharma Does: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.</li>
</ul>
<h3 class="wp-block-heading">Retractable Technologies</h3>
<ul>
<li>The Trade: Retractable Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVP#NYSE">RVP</a>) President and CEO Thomas J Shaw <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 8,788 shares</a> at an average price of $1.09. The insider spent around $9,579 to buy those shares. </li>
<li>What's Happening: On May 15, Retractable Technologies posted a decline in quarterly sales results.</li>
<li>What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39950906/nasdaq-s-p-500-record-worst-session-since-2022-amid-tesla-alphabet-selloff-investor-optimism-decrea">Nasdaq, S&amp;P 500 Record Worst Session Since 2022 Amid Tesla, Alphabet Selloff: Investor Optimism Decreases Further</a></li>
</ul>

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ATYR

Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying

First Financial Northwest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFNW#NASDAQ">FFNW</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.03 by 466.67 percent. This is a 6.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $8.97 million which beat the analyst consensus estimate of $8.77 million by 2.28 percent. This is a 12.99 percent decrease over sales of $10.31 million the same period last year.

Earnings

FFNW

First Financial Northwest Q2 EPS $0.17 Beats $0.03 Estimate, Sales $8.97M Beat $8.77M Estimate

Wedbush analyst David Chiaverini maintains Prosperity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PB#NYSE">PB</a>) with a Neutral and raises the price target from $63 to $75.

Price Target

Analyst Ratings

Wedbush Maintains Neutral on Prosperity Bancshares, Raises Price Target to $75

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains First Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBNC#NASDAQ">FBNC</a>) with a Outperform and raises the price target from $40 to $45.

FBNC

Keefe, Bruyette & Woods Maintains Outperform on First Bancorp, Raises Price Target to $45

U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 0.5% on Thursday.
Shares of Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) fell sharply in today's pre-market trading following a <a href="https://www.benzinga.com/news/earnings/24/07/39943178/ford-q2-earnings-highlights-revenue-beat-eps-miss-transit-vans-hit-record-ev-sales-fall-37">second-quarter earnings miss.</a>
Ford reported second-quarter revenue of $47.8 billion, up 6% year-over-year. The revenue beat a Street consensus estimate of $44 billion according to data from Benzinga Pro. The company reported quarterly earnings per share of 47 cents, missing a Street consensus estimate of 68 cents.
Ford Motor shares dipped 13% to $11.90 in the pre-market trading session.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) shares tumbled 22% to $67.85 in pre-market trading after the company reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.</li>
<li>MaxLinear, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NYSE">MXL</a>) shares declined 18.1% to $18.25 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) shares fell 12.4% to $34.65 in pre-market trading after the company reported a second-quarter EPS miss and issued soft third-quarter guidance.</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) dipped 8.7% to $131.00 in pre-market trading following soft third-quarter guidance.</li>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares fell 8.2% to $6.85 in pre-market trading after the company reported worse-than-expected EPS results.</li>
<li>Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) fell 7.8% to $18.06 in pre-market trading following H1 results.</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) declined 4.6% to $203.84 in pre-market trading after the company lowered FY24 EPS guidance.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) shares fell 3% to $8.23 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39931967/nvidia-mcdonalds-and-2-other-stocks-insiders-are-selling">Nvidia, McDonald&#8217;s And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

Movers

STLA

Ford Posts Downbeat Earnings, Joins MaxLinear, STMicroelectronics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

WIIM

PEGA

Pegasystems shares are trading higher after the company reported better-than-expected Q2 financial results.

Garrett Motion shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY24 guidance.

ACIU

AC Immune shares are trading higher after the company's ACI-35.030  was granted FDA Fast Track Designation for Alzheimer's Disease.

<a href="https://newsroom.aboutrobinhood.com/introducing-joint-investing-accounts/" title="https://newsroom.aboutrobinhood.com/introducing-joint-investing-accounts/">https://newsroom.aboutrobinhood.com/introducing-joint-investing-accounts/</a>

HOOD

'Introducing Joint Investing Accounts at Robinhood' - Robinhood

Keefe, Bruyette &amp; Woods analyst Aidan Hall maintains Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>) with a Market Perform and raises the price target from $219 to $245.

Keefe, Bruyette & Woods Maintains Market Perform on Evercore, Raises Price Target to $245

IMAX

Imax shares are trading higher after the company reported better-than-expected Q2 sales results.

Orion Group shares are trading lower after the company reported worse-than-expected Q2 financial results.

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $65 price target.

CRVO

Canaccord Genuity Maintains Buy on CervoMed, Maintains $65 Price Target

Specialty cancer diagnostics company <a href="https://www.globenewswire.com/Tracker?data=t3b4Qi3upE1ZLqLLT6NN4XQvecSYV8-zZ9a8KMgTc8_EEHkPK8EG61QGKq5UHBmp_LXlpjcbvZtmw8ysMLs5og==">Precipio, Inc.</a> <a href="https://www.globenewswire.com/Tracker?data=M3ZF7UXrkiyrjUChOH4M3Tz9StPaQQQUvpYGZXfTjVkUn1gsv4S0n_7s9SGA9XS2wbY1JO-dKapsQYgl4OFaCqwtdnrNBJte1O3zPVLzFqc=">(NASDAQ:</a><a href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to note that a small contributing factor to the cash increase was the incoming cash collections that were expected in Q1, but were delayed and received in Q2 due to the impact of the Change Healthcare hack, as previously <a href="https://www.globenewswire.com/Tracker?data=fGHmzGw_7kJsd80_mWM9PAQaQ4pQ1-NFTtCDWj3Bd1tSbO60xz8amXp_5NMXEnsdwuBl4G7gmOdn47x-iP0a2UuAEG0qKHlYbah3XnU2dxkJ75leKRudiKdU8ttyfMq9TNEQ2EkyEu5_XrqMHJzV2Sqj4sC35oY_Z8jMkNEui7w=">described</a>. &nbsp;
With cash reserves of approximately $1.3M at the end of Q2-2024, and its current pipeline of business, company management remains optimistic about the prospects of reaching breakeven by year end.

Guidance

PRPO

Precipio Reports $0.3M Cash Generated By Operations In Q2 2024

Wedbush analyst David Chiaverini maintains SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) with a Outperform and raises the price target from $25 to $29.

Wedbush Maintains Outperform on SLM, Raises Price Target to $29

Keefe, Bruyette &amp; Woods analyst Christopher O'Connell maintains Dime Community Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCOM#NASDAQ">DCOM</a>) with a Outperform and raises the price target from $25.5 to $28.

DCOM

Keefe, Bruyette & Woods Maintains Outperform on Dime Community Bancshares, Raises Price Target to $28

Largest Direct University Engagement To Leverage PlanetScope, SkySat, And Planetary Variable Analytics

Planet Labs Extends Contract With Taylor Geospatial Institute To 2026

Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) shares are trading lower after the company reported second-quarter results <a href="https://www.benzinga.com/pressreleases/24/07/n39952101/honeywell-delivers-strong-second-quarter-results-and-beats-earnings-guidance-updates-2024-outlook" target="_blank" rel="noreferrer noopener">and lowered FY24 EPS guidance.</a>
Revenue&nbsp;grew 5% Y/Y (organic:&nbsp;+4% Y/Y) to $9.58 billion, beating the consensus of $9.41 billion.
The sales increase was attributed to double-digit organic&nbsp;sales growth in defense and space, commercial aviation, and building solutions.
Adjusted EPS was&nbsp;$2.49&nbsp;(+8%&nbsp;Y/Y), <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$2.42</a>.
Sales by Segments: Aerospace Technologies $3.89 billion (+16%&nbsp;Y/Y), Industrial Automation&nbsp;$2.51 billion&nbsp;(-8%&nbsp;Y/Y), Building Automation&nbsp;$1.57 billion&nbsp;(+4%&nbsp;Y/Y) and Energy and&nbsp;Sustainability Solutions&nbsp;$1.60 billion&nbsp;(+2%&nbsp;Y/Y).
Operating margin expanded by 10 bps Y/Y to 20.7%, and Segment margin contracted by 10 bps Y/Y to&nbsp;23.0% in the quarter.
Operating cash flow stood at&nbsp;$1.4 billion&nbsp;and free cash flow&nbsp;was&nbsp;$1.1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39880398/honeywell-gears-up-united-airlines-new-737-max-with-cutting-edge-avionics-details" rel="noreferrer noopener">Honeywell Gears Up United Airlines&#8217; New 737 MAX with Cutting-Edge Avionics: Details</a>
Honeywell chairman&nbsp;and CEO&nbsp;Vimal Kapur&nbsp;said,&nbsp;&#8220;While Aerospace continues to lead our growth, we are seeing broader participation across our portfolio, with three of our four segments contributing positive growth for the quarter. All four segments grew sequentially in the quarter as well, giving us further confidence in our expectation of a second half organic growth acceleration.&#8221;
&#8220;We also recently announced two additional deals &#8211; the&nbsp;$1.9 billion&nbsp;acquisition of CAES Systems and the&nbsp;$1.8 billion&nbsp;acquisition of Air Products&#8217; LNG process <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39709835/honeywells-1-81b-power-play-acquires-air-products-lng-tech-to-lead-energy-transition" rel="noreferrer noopener">technology and equipment business</a>.&#8221;
Related: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/06/39412211/honeywell-swoops-in-to-acquire-caes-for-1-9b-boosts-defense-business" rel="noreferrer noopener">Honeywell Swoops In To Acquire CAES For $1.9B, Boosts Defense Business</a>
&#8220;We continue to make significant progress on my key priorities for Honeywell as we accelerate our alignment to three powerful megatrends &#8211; automation, the future of aviation, and energy transition, all underpinned by digitalization.&#8221;
Honeywell held cash and equivalents of about&nbsp;$9.8 billion&nbsp;as of June-end.
The company deployed&nbsp;$6.4 billion&nbsp;of capital to share repurchases, dividends, and capital expenditures.
FY24&nbsp;Outlook: The company raised sales growth to $39.10 billion-$39.70 billion (from $38.5 billion &#8211; $39.3 billion) versus the consensus of $38.76 billion.
Honeywell lowered adjusted EPS&nbsp;guidance to&nbsp;$10.05-$10.25&nbsp;(<a target="_blank" href="https://www.benzinga.com//node/39135922" rel="noreferrer noopener">from $10.15-10.45</a>) versus the estimate of $10.25.
Also, Honeywell reduced the&nbsp;outlook&nbsp;for segment margin to&nbsp;23.3%-23.5%&nbsp;(from&nbsp;23.8%-24.1%), with segment margin contraction of 20 bps- flat.
The company now expects an operating cash flow of&nbsp;$6.6 billion- $7.0 billion and a <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">free&nbsp;cash flow of&nbsp;$5.5 billion &#8211; $5.9 billion</a>.
Investors can gain exposure to the stock via&nbsp;Gabelli Commercial Aerospace And Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCAD#NYSE">GCAD</a>) and&nbsp;Invesco Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPA#NYSE">PPA</a>).
Price Action: HON shares are down 4.52% at $204.00 premarket at the last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Equities

Large Cap

Buybacks

GCAD

Honeywell Beats On Q2 Earnings, Thanks To Aerospace Strength; Lowers FY24 EPS Outlook

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Hold and maintains $89 price target.

BMRN

Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Maintains $89 Price Target

New grocery partnership will offer consumers same-day delivery from hundreds of locations, with SNAP/EBT payment capabilities coming later this year
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavealot.com%2F&amp;esheet=54099448&amp;newsitemid=20240725419604&amp;lan=en-US&amp;anchor=Save+A+Lot&amp;index=1&amp;md5=4a97910c19bf9af67d34fab125471611">Save A Lot</a>, one of the largest discount grocery store chains in the United States with over 750 stores, announced today a new partnership with DoorDash, the local commerce platform. With over 400 stores currently live on the DoorDash Marketplace, consumers can access high-quality fresh products at everyday low prices and enjoy same-day delivery in under an hour, on average.&#x2A; In addition, participating Save A Lot stores will support SNAP/EBT payment capabilities on DoorDash later this year for on-demand delivery of SNAP-eligible groceries.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Ping An Healthcare

News

Latest news for Ping An Healthcare (OTC:PIAHY) Stock